Todd Asset Management LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 13.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 80,280 shares of the company’s stock after buying an additional 9,300 shares during the period. Todd Asset Management LLC’s holdings in Novo Nordisk A/S were worth $2,752,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in NVO. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 25.5% in the fourth quarter. Loomis Sayles & Co. L P now owns 19,057,123 shares of the company’s stock worth $683,388,000 after buying an additional 3,872,745 shares during the last quarter. Sustainable Growth Advisers LP raised its position in shares of Novo Nordisk A/S by 34,479.6% in the third quarter. Sustainable Growth Advisers LP now owns 1,864,530 shares of the company’s stock valued at $77,546,000 after buying an additional 1,859,138 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Novo Nordisk A/S during the third quarter valued at $51,330,000. Capital International Investors raised its position in shares of Novo Nordisk A/S by 39.3% in the third quarter. Capital International Investors now owns 2,690,700 shares of the company’s stock valued at $111,906,000 after buying an additional 758,600 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in Novo Nordisk A/S during the fourth quarter worth about $22,589,000. 6.38% of the stock is owned by institutional investors and hedge funds.
Novo Nordisk A/S (NVO) opened at 43.20 on Friday. The company’s 50-day moving average is $41.60 and its 200-day moving average is $36.77. The company has a market cap of $107.82 billion, a price-to-earnings ratio of 18.86 and a beta of 0.67. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $57.41.
ILLEGAL ACTIVITY NOTICE: “Todd Asset Management LLC Purchases 9,300 Shares of Novo Nordisk A/S (NVO)” was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://transcriptdaily.com/2017/06/17/todd-asset-management-llc-buys-9300-shares-of-novo-nordisk-as-nvo-updated-updated.html.
Several brokerages recently weighed in on NVO. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, March 8th. TheStreet upgraded shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. BidaskClub raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday. Barclays PLC assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, March 7th. They issued an “underweight” rating on the stock. Finally, HSBC Holdings plc downgraded shares of Novo Nordisk A/S from a “hold” rating to a “reduce” rating in a research report on Friday, April 7th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $57.00.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.